Equity Overview
Price & Market Data
Price: $2.09
Daily Change: +$0.11 / 5.26%
Range: $1.86 - $2.10
Market Cap: $35,142,160
Volume: 106,186
Performance Metrics
1 Week: 3.63%
1 Month: -0.50%
3 Months: -31.74%
6 Months: 61.29%
1 Year: -33.33%
YTD: -9.09%
Details
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.